This is one of two pre-specifed quality of life (QOL) analyses of maintenance treatment with PARP inhibitors.
The SOLO2 trial reported that olaparib maintenance therapy did not have significant detrimental effect on health-related quality of life vs.placebo. There were clinically meaningful benefits in time without significant symptoms of toxicity and quality-adjusted progression-free survival
A commentary notes that these two analyses clearly show that neither olaparib nor niraparib has a detrimental effect on QOL in the maintenance setting of platinum-sensitive recurrent ovarian cancer. It suggests that future trials in the maintenance setting should include a predefined patient-reported outcomes (PRO) hypothesis and a statistical analysis plan including appropriate timing and duration of measurements. The completion of PRO instruments can be a burden to patients; thus, limiting PROs to those that inform a study-specific hypothesis can aid in achieving a high compliance rate.